HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Margolis, D. J. Articles by Berlin, J. A. Search for Related Content PubMed PubMed Citation Articles by Margolis, D. J. Articles by Berlin, J. A. Social Bookmarking                What's this?

Effectiveness of Platelet Releasate for the Treatment of Diabetic Neuropathic Foot Ulcers

¹ Dermatology and
² Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

OBJECTIVE—The goal of this study was to specifically estimate the effectiveness of platelet releasate, a widely available treatment administered by a proprietary group of wound care centers (WCCs) for the treatment of diabetic neuropathic foot ulceration.

RESEARCH DESIGN AND METHODS—Treatment effectiveness was estimated in a retrospective cohort study controlling for treatment selection bias using logistic regression–derived propensity scores.

RESULTS—Platelet releasate was more effective than standard care. The relative risk for a wound to heal after treatment with platelet releasate compared with standard care at a WCC varied from 1.14 (95% CI 1.03–1.27) to 1.59 (1.49–1.70). The effect was greatest in those with the most severe wounds, i.e., large wounds that affect deeper anatomical structures.

CONCLUSIONS—Within the limitations of the ability of propensity score analysis to control for selection bias, platelet releasate is more effective than standard therapy. This effect is more pronounced in more severe wounds. Unfortunately, severe wounds have not been evaluated in randomized clinical trials of new interventions. We encourage the inclusion of these patients in future trials.

Abbreviations: CHS, Curative Health Service • FDA, Food and Drug Administration • PR, platelet releasate • WCC, wound care center

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. de Mos, A. E. van der Windt, H. Jahr, H. T. M. van Schie, H. Weinans, J. A. N. Verhaar, and G. J. V. M. van Osch Can Platelet-Rich Plasma Enhance Tendon Repair?: A Cell Culture Study Am. J. Sports Med., June 1, 2008; 36(6): 1171 - 1178. [Abstract] [Full Text] [PDF]

				D. B. Hom, B. M. Linzie, and T. C. Huang The Healing Effects of Autologous Platelet Gel on Acute Human Skin Wounds Arch Facial Plast Surg, May 1, 2007; 9(3): 174 - 183. [Abstract] [Full Text] [PDF]

				M. Sanchez, E. Anitua, J. Azofra, I. Andia, S. Padilla, and I. Mujika Comparison of Surgically Repaired Achilles Tendon Tears Using Platelet-Rich Fibrin Matrices Am. J. Sports Med., February 1, 2007; 35(2): 245 - 251. [Abstract] [Full Text] [PDF]

				C. W Smith, R. S Binford, D. W Holt, and D. P Webb Quality assessment of platelet rich plasma during anti-platelet therapy Perfusion, January 1, 2007; 22(1): 41 - 50. [Abstract] [PDF]

				J. P. McAleer, E. Kaplan, and G. Persich Efficacy of concentrated autologous platelet-derived growth factors in chronic lower-extremity wounds. J Am Podiatr Med Assoc, November 1, 2006; 96(6): 482 - 488. [Abstract] [Full Text] [PDF]

				F. Giacco, G. Perruolo, E. D'Agostino, G. Fratellanza, E. Perna, S. Misso, G. Saldalamacchia, F. Oriente, F. Fiory, C. Miele, et al. Thrombin-activated platelets induce proliferation of human skin fibroblasts by stimulating autocrine production of insulin-like growth factor-1 FASEB J, November 1, 2006; 20(13): 2402 - 2404. [Abstract] [Full Text] [PDF]

				L. Liu, D. Hartwig, S. Harloff, P. Herminghaus, T. Wedel, K. Kasper, and G. Geerling Corneal epitheliotrophic capacity of three different blood-derived preparations. Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2438 - 2444. [Abstract] [Full Text] [PDF]

				D. M. Ranly, J. McMillan, T. Keller, C. H. Lohmann, T. Meunch, D. L. Cochran, Z. Schwartz, and B. D. Boyan Platelet-Derived Growth Factor Inhibits Demineralized Bone Matrix-Induced Intramuscular Cartilage and Bone Formation. A Study of Immunocompromised Mice J. Bone Joint Surg. Am., September 1, 2005; 87(9): 2052 - 2064. [Abstract] [Full Text] [PDF]

				D. G. Armstrong, L. A. Lavery, H. R. Kimbriel, B. P. Nixon, and A. J.M. Boulton Activity Patterns of Patients With Diabetic Foot Ulceration: Patients with active ulceration may not adhere to a standard pressure off-loading regimen Diabetes Care, September 1, 2003; 26(9): 2595 - 2597. [Abstract] [Full Text] [PDF]

				D. J. Margolis, J. M. Gelfand, O. Hoffstad, and J. A. Berlin Surrogate End Points for the Treatment of Diabetic Neuropathic Foot Ulcers Diabetes Care, June 1, 2003; 26(6): 1696 - 1700. [Abstract] [Full Text] [PDF]

				D. J. Margolis, L. Allen-Taylor, O. Hoffstad, and J. A. Berlin Diabetic Neuropathic Foot Ulcers: The association of wound size, wound duration, and wound grade on healing Diabetes Care, October 1, 2002; 25(10): 1835 - 1839. [Abstract] [Full Text] [PDF]